Company
-
Publications
2022
1) Symonds EL, Pedersen SK, Yeo B, Al Naji H, Byrne
SE, Roy A, Young GP. Assessment of tumor burden and
response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1. Mol Oncol. 2022 Jan 9. doi:
10.1002/1878-0261.13178. Epub ahead of print. PMID: 350002642021
1) Young GP, Symonds EL, Nielsen HJ, Ferm L,
Christensen IJ, Dekker E, van der Vlugt M, Mallant-Hent RC, Boulter N, Yu B, Chan M, Tevz G, LaPointe LC, Pedersen SK. Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer. Clin Epigenetics. 2021 Jan 21;13(1):14. doi:
10.1186/s13148-020-00999-y. PMID: 33478584; PMCID: PMC78187742020
1) Musher et al. Evaluation of Circulating Tumor DNA for Methylated BCAT1 and IKZF1 to Detect Recurrence of Stage II/ Stage III Colorectal Cancer. Cancer Epidemiology, Biomarkers & Prevention. September 2020
2) Symonds et al. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer. Cancer. January 20202019
1) Symonds et al. A randomised controlled trial testing provision of fecal and blood test options on participation for colorectal
cancer screening. Cancer Prevention Research. 2 July 20192018
1) Saluja et al. The Use of Circulating Tumor DNA for
Prognosis of Gastrointestinal Cancers. Frontiers in Oncology. 24 July 2018
2) Murray et al. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
Journal of Cancer Research and Clinical Oncology. 10 July 2018
3) Symonds et al. Circulating tumour DNA for monitoring
colorectal cancer—a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection. Clinical Epigenetics. 16 May 2018
4) Jedi et al. Methylation and Gene Expression of BCAT1 and IKZF1 in Colorectal Cancer Tissues. Clinical Medicine Insights: Oncology. 10 May 20182017
1) Shapiro et al. A Comparison of Fecal Immunochemical and High-Sensitivity Guaiac Tests for Colorectal Cancer Screening. Am J Gastroenterol advance online publication. 10 October 2017; doi:10.1038/ajg.2017.28
2) Murray et al. Validation of a Circulating Tumor-Derived DNA Blood Test for Detection of Methylated BCAT1 and IKZF1 DNA. JALM. 2017, doi: 10.1373/jalm.2017.0231352016
1) Mitchell et al. Evaluation of Methylation Biomarkers
for Detection of Circulating Tumor DNA and Application to Colorectal Cancer. Genes. 2016, 7(12), 125; doi:10.3390/genes712012
2) Young et al. A Cross-sectional Study Comparing a Blood Test for
Methylated BCAT1 and IKZF1 Tumor-derived DNA with CEA for Detection of Recurrent Colorectal Cancer. Cancer Medicine. doi:10.1002/cam4.868
3) Symonds et al. A Blood Test for
Methylated BCAT1 and IKZF1 vs. a Fecal Immunochemical Test
for Detection of Colorectal Neoplasia. Clin Trans Gastro. 2016; 7, e1372015
1) Pedersen et al. A Two-Gene Blood Test for Methylated DNA Sensitive for Colorectal Cancer. PLoS One. 2015;10(4):e012504
2) Symonds et al. Improving Participation in Colorectal
Cancer Screening: a Randomised Controlled Trial of Sequential Offers of Fecal then Blood Based Non-Invasive Tests. Asian Pac J Cancer. Prev, 16 (18), 8455-846
3) Pedersen et al. Evaluation of an Assay for Methylated BCAT1 and IKZF1 in Plasma for Detection ofColorectal Neoplasia. BMC CANCER. 15(1):654. October 20152014
1) Mitchell et al. A Panel of Genes Methylated with High Frequency in Colorectal Cancer. BMC Cancer. 2014;14:5
2) Pedersen et al. CAHM, a Long Non-Coding RNA Gene
Hypermethylated in Colorectal Neoplasia. Epigenetics. 2014 Aug;9(8):1071-822012
1) LaPointe et al. Discovery and Validation of MolecularBiomarkers for Colorectal Adenomas and Cancer with Application to BloodTesting. PLoS One. 2012;7(1):e29059
2)Collins et al. Screening for
Colorectal Cancer and Advanced Colorectal Neoplasia in Kidney Transplant Recipients: Cross Sectional Prevalence and Diagnostic Accuracy Study of Fecal Immunochemical Testing for Hemoglobin and Colonoscopy. BMJ. 2012 Jul
25;345:e46572011
1) Graham et al. Colorectal Neoplasia Differentially
Expressed (CRNDE), a Novel Gene with Elevated Expression in Colorectal Adenomas and Adenocarcinomas. Genes Cancer. 2011 Aug;2(8):829-402008
1) LaPointe et al. Map of Differential Transcript Expression
in the Normal Human Large Intestine. Physiol Genomics. 2008 Mar 14;33(1):50-642006
1) Smith et al. Comparison of a Brush-Sampling Fecal
Immunochemical Test for Hemoglobin with a Sensitive Guaiac-Based Fecal Occult
Blood Test in Detection of Colorectal Neoplasia. Cancer. 2006 Nov 1;107(9):2152-92003
1) Cole et al. A Randomised Trial of the Impact of New
Fecal Hemoglobin Test Technologies on Population Participation in Screening for
Colorectal Cancer. J Med Screen. 2003;10(3):117-2
2)Young et al. PrescreeningEvaluation of a Brush-Based Fecal Immunochemical Test for Hemoglobin. J Med Screen. 2003;10(3):123-8 -
Posters
2019
1) Pedersen et al. Performance Evaluation of a Blood Test
Assaying for ctDNA Methylated in IRF4, BCAT1, IKZF1 for Detection of Colorectal Cancer. UEGW Week October 2019.
2) Symonds et al. Performance Comparison of the
Methylated BCAT1/IKZF1 ctDNA Test (Colvera) with the CEA Assay for Detection of Recurrent Colorectal Cancer. ASCO Annual Meeting.2018
1) Symonds et al. Specificity of methylated BCAT1 and IKZF1 for colorectal cancer. ASCO GI.
2) Young et al. Methylated circulating tumor-derived DNA for detection of colorectal cancer – relationship of methylated BCAT1 or IKZF1 to tissue expression and comparison with FIT. Early Detection Research Network Annual Meeting.
3) Symonds et al. Circulating Tumor DNA to Assess
Characteristics of Colorectal Cancer and Completeness of Surgical Resection. Digestive Disease Week Annual Meeting.
4) Detection of ctDNA biomarkers post resection and relationship to recurrent disease in colorectal cancer patients. Online abstract publications at ASCO.
5) Murray et al. A prospective cohort study in
colorectal cancer assessing the relationship between post-surgery detection of
methylated BCAT1 or IKZF1 ctDNA and risk for residual disease and survival. ASCO Annual Meeting.2017
1) Symonds et al. Predictors of circulating tumor-derived methylated BCAT1 and IKZF1 DNA in colorectal cancer patients. ASCO GI Symposium.
2) Symonds et al. The relationship between the degree of
aberrant methylation in colorectal cancer tissue and appearance of tumor-derived DNA in blood. ASCO GI Symposium.
3) Symonds et al. Circulating tumor DNA before and
after resection for colorectal cancer. ASCO Annual Meeting.
4) Alsobrook et al. Analytical validation of a circulating tumor methylated-DNA assay for detection of colorectal cancer recurrence. AMP Annual
Meeting.
5) Boulter et al. A droplet digital PCR assay for detection of methylated BCAT1 and IKZF1 in circulating tumor DNA. AMP Annual Meeting.
6) Murray et al. Effect of blood collection tubes on
circulating tumor DNA (ctDNA) yield and specificity. AMP Annual Meeting.2016
1) Pedersen et al. A novel 2-gene blood test for colorectal cancer recurrence. ASCO GI Symposium.
2) Symonds et al. Symonds et al. ASCO GI Symposium.2015
1) Baker et al. Detection of variable methylation patterns improves sensitivity of a colorectal cancer blood test. Digestive Disease Week.
2) Symonds et al. Improving participation rates in community-based colorectal cancer screening – role of a blood test. Digestive Disease Week.
3) Symonds et al. Methylated BCAT1 and IKZF1 DNA in plasma as novel biomarkers for colorectal cancer recurrence. Digestive Disease Week.
4) Symonds et al. Comparison of a methylated two-gene (BCAT1-IKZF1) blood test to FIT for detection of colorectal neoplasia. Digestive Disease Week.
5) Mangira et al. The
morphological features of colorectal tumors that are associated with the appearance of methylated DNA in plasma. Digestive Disease Week.
6) Vol. 10, Issue Suppl. S9,
p211-212.. Asia-Pacific Journal of Clinical Oncology. 2015 DOI:
10.1111/ajco.123322014
1) Baker et al. Detection of variable methylation patterns improves colorectal cancer blood test sensitivity. AGW.
2) Symonds et al. A methylated
DNA blood test for colorectal cancer screening returns a lower false positivity rate than a faecal immunochemical test in people with benign bleeding conditions. AGW.
3) Mangira et al. Appearance of
tumor-associated methylated DNA in plasma correlates with colorectal tumour invasion. Flinders Centre for Innovation in Cancer.
4) Baker et al. Method validation of a laboratory–developed blood test for colorectal cancer. Combio2014 Conference. 2014;11:13028
5) Young. Evaluation of a 2-gene
(IKZF1 and BCAT1) DNA blood test for detection of colorectal cancer. Digestive
Disease Week.
6) Redwood et al. Comparison
of Fecal Occult Blood Tests for Colorectal Cancer Screening in an Alaska Native Population With High Prevalence of Helicobacter pylori Infection, 2008-2012.
Prev Chronic Dis. 2014;11:13028
7) Mitchell et al.
Colorectal cancer methylation biomarkers. Keystone Symposia Conference. Cancer
Epigenetics. 20142013
1) Baker et al. Clinical evaluation of a novel
duplexed 2-gene DNA methylation blood test for colorectal cancer. Lorne Genome Conference.
2) Rand et al. Development of
non-bisulphite-based assays for colorectal cancer DNA methylation
markers. Gordon Research Conference. Cancer Genetics & Epigenetics.2012
1) Pedersen. Novel methylation DNA biomarkers for
colorectal neoplasia: From tissue to blood. WEO Colorectal Cancer Screening
Committee Meeting.
2) Pedersen. Discovery and
validation of a novel DNA methylation biomarker for colorectal cancer with
application to blood testing. Digestive Disease Week.
3) Baker et al. Clinical Evaluation of a novel 2-gene
methylation blood test for colorectal cancer. Australian Gastroenterology Week.2011
1)Thomas et al. Plasma Testing of Gene Expression Biomarkers for Colorectal Neoplasia discovered in Neoplastic Colorectal Tissue. Digestive Disease Week (AGA).
2009
1) Pedersen et al. A novel colorectal neoplasia
gene (CRNG) with high sensitivity and specificity for both adenomas and
carcinomas. Digestive Disease Week (AGA).
2) LaPointe et al. Biomarkers
with high sensitivity and specificity for colorectal adenomas and carcinomas.
Digestive Disease Week (AGA).
3) Pedersen et al.
Alternative splicing of S100A11 in colorectal adenomas and carcinomas.
Digestive Disease Week (AGA).
4) Moynihanet al. Upregulation of mesolthelin, RegIV,
and transcobalamin in colon adenomas and cancer. Digestive Disease Week (AGA).2006
1) Wilson et al. Associative gene networks from
microarray data in the normal colon. CSIRO Mathematical and Informational Sciences Annual Divisional Conference.
2) LaPointe et al. Mapping gene
expression along the anterior-posterior axis of the adult human colon. Digestive Disease Week (AGA).2005
1) LaPointe et al. Comparison of classification
methodologies to discover biomarkers from gene expression data. Australian
Microarrays Conference (AMATA).
2) Kiiveri et al. Canonical
Variate Analysis and Microarrays. Australian Microarrays Conference (AMATA).
3) LaPointe et al. Comparison of
machine learning techniques to identify biomarkers for colorectal cancer in
publicly available data. International Society of Computational Biology.
4)LaPointe et al. Identification
of colorectal cancer biomarkers using publicly available gene expression data.
Digestive Disease Week (AGA), Chicago.2004
1) Young et al. A quantifiable fecal immunochemical
test (FIT) for hemoglobin facilitates balancing sensitivity with specificity when screening for colorectal cancer. European Gastroenterology Week.
2) Smith et al. A quantifiable
faecal immunochemical test (FIT) for haemoglobin balancing sensitivity with specificity when screening for colorectal cancer. J. Gastro Hepatology.
19(Suppl): A195
3) Smith et al. A quantifiable
faecal immunochemical test (FIT) for haemoglobin balancing sensitivity with
specificity when screening for colorectal cancer. Gastroenterology. 126(Suppl),2003
1) LaPointe et al. Analysis of mRNA expression profiles
in colorectal adenomas using k-nearest neighbor cluster analysis. Digestive Disease Week (AGA).
2) LaPointe et al. Selecting for
diagnostic colonoscopy by quantifiable fecal immunochemical tests.
Gastroenterology. Supplement to 124(4)2000
1) Sinatra et al. Faecal hemoglobin measurement in
colorectal neoplasia. J Gastro Hepatology. Supplement to 15, 2000